Ocugen Target of Unusually High Options Trading (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) saw unusually large options trading on Monday. Stock investors purchased 4,596 call options on the company. This represents an increase of approximately 93% compared to the average volume of 2,382 call options.

Ocugen Stock Down 9.0 %

OCGN opened at $1.71 on Wednesday. The business’s fifty day simple moving average is $1.07 and its 200 day simple moving average is $0.66. Ocugen has a 52 week low of $0.35 and a 52 week high of $2.11. The stock has a market cap of $438.62 million, a PE ratio of -5.18 and a beta of 3.51. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. WINTON GROUP Ltd bought a new position in shares of Ocugen during the first quarter valued at about $25,000. Belpointe Asset Management LLC grew its stake in shares of Ocugen by 11,550.5% during the first quarter. Belpointe Asset Management LLC now owns 34,835 shares of the company’s stock valued at $30,000 after buying an additional 34,536 shares during the last quarter. Two Sigma Securities LLC bought a new position in shares of Ocugen during the second quarter valued at about $32,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Ocugen during the second quarter valued at about $32,000. Finally, Lazard Asset Management LLC grew its stake in shares of Ocugen by 123.9% during the second quarter. Lazard Asset Management LLC now owns 61,432 shares of the company’s stock valued at $32,000 after buying an additional 33,991 shares during the last quarter. 10.27% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research note on Wednesday, April 3rd.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.